95 related articles for article (PubMed ID: 27508051)
1. Ursolic acid attenuates temozolomide resistance in glioblastoma cells by downregulating O(6)-methylguanine-DNA methyltransferase (MGMT) expression.
Zhu Z; Du S; Ding F; Guo S; Ying G; Yan Z
Am J Transl Res; 2016; 8(7):3299-308. PubMed ID: 27508051
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma.
Han X; Abdallah MOE; Breuer P; Stahl F; Bakhit Y; Potthoff AL; Pregler BEF; Schneider M; Waha A; Wüllner U; Evert BO
Neoplasia; 2023 Oct; 44():100929. PubMed ID: 37634280
[TBL] [Abstract][Full Text] [Related]
3. Identification of TMZ resistance-associated histone post-translational modifications in glioblastoma using multi-omics data.
Ye L; Gu L; Wang Y; Xing H; Li P; Guo X; Wang Y; Ma W
CNS Neurosci Ther; 2024 Mar; 30(3):e14649. PubMed ID: 38448295
[TBL] [Abstract][Full Text] [Related]
4. Overcoming Temozolomide Resistance in Glioblastoma via Enhanced NAD
Li J; Koczor CA; Saville KM; Hayat F; Beiser A; McClellan S; Migaud ME; Sobol RW
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892832
[TBL] [Abstract][Full Text] [Related]
5. Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O
Yousefi Y; Nejati R; Eslahi A; Alizadeh F; Farrokhi S; Asoodeh A; Mojarrad M
J Neurooncol; 2024 May; ():. PubMed ID: 38762829
[TBL] [Abstract][Full Text] [Related]
6. A Novel Blood-Brain Barrier-Permeable Chemotherapeutic Agent for the Treatment of Glioblastoma.
Ozawa T; Rodriguez M; Zhao G; Yao TW; Fischer WN; Jandeleit B; Koller K; Nicolaides T
Cureus; 2021 Aug; 13(8):e17595. PubMed ID: 34646647
[TBL] [Abstract][Full Text] [Related]
7. A modified nucleoside O6-methyl-2'-deoxyguanosine-5'-triphosphate exhibits anti-glioblastoma activity in a caspase-independent manner.
Wang ZH; Li J; Liu Q; Qian JC; Li QQ; Wang QY; Zeng LT; Li SJ; Gao X; Pan JX; Gao XF; Wu K; Hu GX; Iwakuma T; Cai JP
Pharmacol Res; 2024 Jan; 199():106990. PubMed ID: 37984506
[TBL] [Abstract][Full Text] [Related]
8. MGMT function determines the differential response of ATR inhibitors with DNA-damaging agents in glioma stem cells for GBM therapy.
Leong VWS; Khan S; Sharma P; Wu S; Thomas RR; Li X; Singh SK; Lang FF; Yung AWK; Koul D
Neurooncol Adv; 2024; 6(1):vdad165. PubMed ID: 38213834
[TBL] [Abstract][Full Text] [Related]
9. A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas.
Lamb LS; Pereboeva L; Youngblood S; Gillespie GY; Nabors LB; Markert JM; Dasgupta A; Langford C; Spencer HT
Sci Rep; 2021 Oct; 11(1):21133. PubMed ID: 34702850
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic selection through cell death: stochastic modelling of O-6-methylguanine-DNA methyltransferase dynamics.
Lasri A; Juric V; Verreault M; Bielle F; Idbaih A; Kel A; Murphy B; Sturrock M
R Soc Open Sci; 2020 Jul; 7(7):191243. PubMed ID: 32874597
[TBL] [Abstract][Full Text] [Related]
11. Depletion of Kruppel-like factor 15 sensitized gliomas to temozolomide cytotoxicity through
Qu X; Liu X; Zhang Y; Shi Z; Wang X
Biochem Biophys Rep; 2021 Sep; 27():101058. PubMed ID: 34222684
[TBL] [Abstract][Full Text] [Related]
12. Repair of 3-methyladenine and abasic sites by base excision repair mediates glioblastoma resistance to temozolomide.
Bobola MS; Kolstoe DD; Blank A; Chamberlain MC; Silber JR
Front Oncol; 2012; 2():176. PubMed ID: 23230562
[TBL] [Abstract][Full Text] [Related]
13. Circadian regulation of
Gonzalez-Aponte MF; Damato AR; Trebucq LL; Simon T; Cárdenas-García SP; Cho K; Patti GJ; Golombek DA; Chiesa JJ; Herzog ED
bioRxiv; 2023 Sep; ():. PubMed ID: 37745358
[TBL] [Abstract][Full Text] [Related]
14. Current trends in targeted therapies for glioblastoma multiforme.
Ohka F; Natsume A; Wakabayashi T
Neurol Res Int; 2012; 2012():878425. PubMed ID: 22530127
[TBL] [Abstract][Full Text] [Related]
15. Enhancing temozolomide antiglioma response by inhibiting O6-methylguanine-DNA methyltransferase with selected phytochemicals: in silico and in vitro approach.
Vibhavari RJA; Rao V; Cheruku SP; Kumar BH; Maity S; Nandakumar K; Kumar L; Mehta CH; Nayak U; Chamallamudi MR; Kumar N
3 Biotech; 2023 Dec; 13(12):385. PubMed ID: 37928438
[TBL] [Abstract][Full Text] [Related]
16.
Safaei R; Mojtahedi H; Hanaei S; Razavi A; Esmaeili M; Sadr M; Rezaei A; Edalatfar M; Kashani HK; Sadeghi-Naini M; Darbeheshti F; Gharehdaghi J; Forouzesh M; Ebrahimi A; Rezaei N
Avicenna J Med Biotechnol; 2023; 15(1):48-52. PubMed ID: 36789113
[TBL] [Abstract][Full Text] [Related]
17. Current promising treatment strategy for glioblastoma multiform: A review.
Bahadur S; Sahu AK; Baghel P; Saha S
Oncol Rev; 2019 Jul; 13(2):417. PubMed ID: 31410248
[TBL] [Abstract][Full Text] [Related]
18. Selective regulation of chemosensitivity in glioblastoma by phosphatidylinositol 3-kinase beta.
Pridham KJ; Hutchings KR; Beck P; Liu M; Xu E; Saechin E; Bui V; Patel C; Solis J; Huang L; Tegge A; Kelly DF; Sheng Z
iScience; 2024 Jun; 27(6):109921. PubMed ID: 38812542
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide, Procarbazine and Nitrosoureas in the Therapy of Malignant Gliomas: Update of Mechanisms, Drug Resistance and Therapeutic Implications.
Kaina B
J Clin Med; 2023 Nov; 12(23):. PubMed ID: 38068493
[TBL] [Abstract][Full Text] [Related]
20. An Insight into Emerging Phytocompounds for Glioblastoma Multiforme Therapy.
Prakash V; Gabrani R
Cardiovasc Hematol Agents Med Chem; 2023 Nov; ():. PubMed ID: 37957904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
